151 related articles for article (PubMed ID: 25501662)
21. LMO4 modulates proliferation and differentiation of 3T3-L1 preadipocytes.
Wang N; Wang X; Shi M; Shi H; Yan X; Li H; Wang S; Wang Y
FEBS Lett; 2013 Sep; 587(18):3032-7. PubMed ID: 23892074
[TBL] [Abstract][Full Text] [Related]
22. Recruitment and activation of SLK at the leading edge of migrating cells requires Src family kinase activity and the LIM-only protein 4.
Baron KD; Al-Zahrani K; Conway J; Labrèche C; Storbeck CJ; Visvader JE; Sabourin LA
Biochim Biophys Acta; 2015 Jul; 1853(7):1683-92. PubMed ID: 25882817
[TBL] [Abstract][Full Text] [Related]
23. Ginkgolide B protects against cisplatin-induced ototoxicity: enhancement of Akt-Nrf2-HO-1 signaling and reduction of NADPH oxidase.
Ma W; Hu J; Cheng Y; Wang J; Zhang X; Xu M
Cancer Chemother Pharmacol; 2015 May; 75(5):949-59. PubMed ID: 25749575
[TBL] [Abstract][Full Text] [Related]
24. Rapamycin alleviates cisplatin-induced ototoxicity in vivo.
Fang B; Xiao H
Biochem Biophys Res Commun; 2014 Jun; 448(4):443-7. PubMed ID: 24796670
[TBL] [Abstract][Full Text] [Related]
25. LMO4 inhibits p53-mediated proliferative inhibition of breast cancer cells through interacting p53.
Zhou X; Sang M; Liu W; Gao W; Xing E; Lü W; Xu Y; Fan X; Jing S; Shan B
Life Sci; 2012 Sep; 91(9-10):358-63. PubMed ID: 22906635
[TBL] [Abstract][Full Text] [Related]
26. Dose dependent protection by lipoic acid against cisplatin-induced ototoxicity in rats: antioxidant defense system.
Rybak LP; Husain K; Whitworth C; Somani SM
Toxicol Sci; 1999 Feb; 47(2):195-202. PubMed ID: 10220857
[TBL] [Abstract][Full Text] [Related]
27. Heat shock protein 70 and cellular disturbances in cochlear cisplatin ototoxicity model.
García-Berrocal JR; Nevado J; González-García JA; Sánchez-Rodríguez C; Sanz R; Trinidad A; España P; Citores MJ; Ramírez-Camacho R
J Laryngol Otol; 2010 Jun; 124(6):599-609. PubMed ID: 20307356
[TBL] [Abstract][Full Text] [Related]
28. The structure of an LIM-only protein 4 (LMO4) and Deformed epidermal autoregulatory factor-1 (DEAF1) complex reveals a common mode of binding to LMO4.
Joseph S; Kwan AH; Stokes PH; Mackay JP; Cubeddu L; Matthews JM
PLoS One; 2014; 9(10):e109108. PubMed ID: 25310299
[TBL] [Abstract][Full Text] [Related]
29. Regulator of G protein signaling 17 represents a novel target for treating cisplatin induced hearing loss.
Dhukhwa A; Al Aameri RFH; Sheth S; Mukherjea D; Rybak L; Ramkumar V
Sci Rep; 2021 Apr; 11(1):8116. PubMed ID: 33854102
[TBL] [Abstract][Full Text] [Related]
30. Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein.
Singh RR; Barnes CJ; Talukder AH; Fuqua SA; Kumar R
Cancer Res; 2005 Nov; 65(22):10594-601. PubMed ID: 16288053
[TBL] [Abstract][Full Text] [Related]
31. Up-regulation of adenosine receptors in the cochlea by cisplatin.
Ford MS; Nie Z; Whitworth C; Rybak LP; Ramkumar V
Hear Res; 1997 Sep; 111(1-2):143-52. PubMed ID: 9307320
[TBL] [Abstract][Full Text] [Related]
32. Mechanism of cisplatin ototoxicity: antioxidant system.
Ravi R; Somani SM; Rybak LP
Pharmacol Toxicol; 1995 Jun; 76(6):386-94. PubMed ID: 7479581
[TBL] [Abstract][Full Text] [Related]
33. Trichostatin A protects against cisplatin-induced ototoxicity by regulating expression of genes related to apoptosis and synaptic function.
Wang P; Zhang P; Huang J; Li M; Chen X
Neurotoxicology; 2013 Jul; 37():51-62. PubMed ID: 23558232
[TBL] [Abstract][Full Text] [Related]
34. LMO4 Is a Disease-Provocative Transcription Coregulator Activated by IL-23 in Psoriatic Keratinocytes.
Tu Z; Zhang S; Zhou G; Zhou L; Xiang Q; Chen Q; Zhao P; Zhan H; Zhou H; Sun L
J Invest Dermatol; 2018 May; 138(5):1078-1087. PubMed ID: 29258893
[TBL] [Abstract][Full Text] [Related]
35. Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.
Mukherjea D; Jajoo S; Kaur T; Sheehan KE; Ramkumar V; Rybak LP
Antioxid Redox Signal; 2010 Sep; 13(5):589-98. PubMed ID: 20214492
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent cochlear and vestibular toxicity of trans-tympanic cisplatin in the rat.
Callejo A; Durochat A; Bressieux S; Saleur A; Chabbert C; Domènech Juan I; Llorens J; Gaboyard-Niay S
Neurotoxicology; 2017 May; 60():1-9. PubMed ID: 28223157
[TBL] [Abstract][Full Text] [Related]
37. Contribution of DEAF1 structural domains to the interaction with the breast cancer oncogene LMO4.
Cubeddu L; Joseph S; Richard DJ; Matthews JM
PLoS One; 2012; 7(6):e39218. PubMed ID: 22723967
[TBL] [Abstract][Full Text] [Related]
38. Lmo4 and Other LIM domain only factors are necessary and sufficient for multiple retinal cell type development.
Jin K; Xiao D; Andersen B; Xiang M
Dev Neurobiol; 2016 Aug; 76(8):900-15. PubMed ID: 26579872
[TBL] [Abstract][Full Text] [Related]
39. Cisplatin ototoxicity to the rat inner ear: a role for HMG1 and iNOS.
Li G; Liu W; Frenz D
Neurotoxicology; 2006 Jan; 27(1):22-30. PubMed ID: 16125245
[TBL] [Abstract][Full Text] [Related]
40. LMO4 is required to maintain hypothalamic insulin signaling.
Pandey NR; Zhou X; Zaman T; Cruz SA; Qin Z; Lu M; Keyhanian K; Brunel JM; Stewart AF; Chen HH
Biochem Biophys Res Commun; 2014 Jul; 450(1):666-72. PubMed ID: 24937445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
